Ceftriaxone contraindications: Difference between revisions
Created page with "_NOTOC__ {{Ceftriaxone}} {{CMG}};{{AE}}{{AK}} Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics. '''Neonat..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Ceftriaxone}} | {{Ceftriaxone}} | ||
{{CMG}};{{AE}}{{AK}} | {{CMG}};{{AE}}{{AK}} | ||
Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics. | Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics. | ||
Latest revision as of 17:36, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
Neonates (≤28 days)
Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a possible risk of bilirubin encephalopathy in these patients.
Ceftriaxone for injection is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY, WARNINGS and DOSAGE AND ADMINISTRATION).
A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone for injection and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates.
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050796lbl.pdf